Global Cardiac Biomarkers Market Insights Forecasts to 2033

• The Global Cardiac Biomarkers Market Size was Valued at USD 18.40 Billion in 2023
• The Market Size is Growing at a CAGR of 14.20% from 2023 to 2033
• The Worldwide Cardiac Biomarkers Market Size is Expected to Reach USD 69.44 Billion by 2033
• Asia-Pacific is expected to Grow the fastest during the forecast period

The Global Cardiac Biomarkers Market Size is Anticipated to Exceed USD 69.44 Billion by 2033, Growing at a CAGR of 14.20% from 2023 to 2033.

Market Overview

Cardiac biomarkers are endogenous substances released into the bloodstream when heart muscle is damaged or stressed. It is prevention of heart diseases by monitoring heart cardiac biomarkers testing is profound approach for obtaining rapid results for immediate diagnosis and treatment. Cardiac biomarkers are used to classify the risk of a variety of cardiovascular illnesses (CVDs), such as myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). CK-MB, troponin I & T, myoglobin, BNPs, IMA, and a few others are cardiac biomarkers commonly employed as part of an integrated diagnostic approach for CVDs. Over the last five to six years, market for cardiac biomarkers has grown significantly. Healthcare providers are now focusing on detecting these markers to identify and diagnose critical conditions like myocardial infarction, heart attack, and acute coronary syndrome. Market players have developed tests to accurately detect these biomarkers, aiding in early diagnosis. The cardiac biomarkers market is poised for continued innovation, driven by the integration of digital health solutions and artificial intelligence into diagnostic tools. The growing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is projected to boost the global cardiac biomarkers markets during the forecast period.

Report Coverage

This research report categorizes the market for the global cardiac biomarkers market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global cardiac biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global cardiac biomarkers market.

Driving Factors

An increase in the prevalence of cardiovascular diseases is expected to boost global cardiac biomarkers market growth. The market is expected to rise due to robust research and development in cardiovascular therapies, as well as the launch of quick and new biomarker tests. Several emerging markets, including India, provide significant growth opportunities for suppliers of cardiac diagnostic solutions because of the rising population of heart patients. The increased burden of cardiovascular diseases in these countries is caused by a variety of conditions, including high blood pressure, diabetes, obesity, and so on, offering opportunities for suppliers. Developing clinical research investigations aiming to uncover novel cardiac biomarkers. The market is predicted to rise because of an increase in research and development initiatives aimed at enhancing the effectiveness of cardiac biomarker-based diagnostics. Hence, these factors are significant growth of the global cardiac biomarkers market during the forecast period.

Restraining Factors

Limited specificity in some circumstances, as well as adverse effects such as skeletal muscle injury, are limiting the expansion of the cardiac biomarker markets. Lack of availability of POC testing kits & delayed test results. Also, technical issues related to the collection and storage of samples are expected to hinder market growth. Hence, these factors may hamper the market growth of the global cardiac biomarkers market during the forecast period.

Market Segmentation

The global cardiac biomarkers market share is classified into type, application, biomarker, and end user.

• The troponins segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period.

Based on the type, the global cardiac biomarkers market is divided into creatine kinase, troponins, myoglobin, ischemia modified albumin, and other types. Among these, the troponins segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period. The segmental growth can be attributed to the troponin test is used to diagnose several conditions, including myocardial infarction and acute coronary syndrome. Increasing the prevalence of myocardial infraction and acute coronary syndrome leads to rising demand for troponin tests during the forecast period.

• The acute coronary syndrome segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period.   

Based on the application, the global cardiac biomarkers market is divided into acute coronary syndrome and myocardial infarction. Among these, the acute coronary syndrome segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period. The growth can be attributable to the increasing prevalence of acute coronary syndrome is boosts the segmental growth.

• The troponin segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period.

Based on the biomarker, the global cardiac biomarkers market is divided into troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and others. Among these, troponin is expected to hold the largest share of the global cardiac biomarkers market during the forecast period. The segmental growth can be attributed to the troponin biomarkers have significant functions in diagnosing cardiac diseases, measuring the severity of cardiac events, guiding therapy decisions, and predicting patient outcomes.

• The hospitals segment is expected to hold the largest share of the global cardiac biomarkers market during the forecast period.

Based on the end user, the global cardiac biomarkers market is divided into hospitals and specialty clinics. Among these, the hospitals is expected to hold the largest share of the global cardiac biomarkers market during the forecast period. The segmental growth can be attributed to the rapidly increasing hospital infrastructure in emerging nations, as well as clinical laboratories being integrated into large hospitals, which have contributed to increased global usage of cardiac biomarker tests.

Regional Segment Analysis of the Global Cardiac Biomarkers Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• Latin America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global cardiac biomarkers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global cardiac biomarkers market over the predicted timeframe. The regional growth can be attributed to the developed healthcare infrastructure and high adoption of cardiac biomarkers as a tool for diagnosis and prognostic diagnosis conditions. The increasing elderly population requires biomarker testing to detect diseases like acute myocardial infarction, which drives the demand for testing goods. increases cardiovascular disease risk and puts additional pressure on the health system leading to demand for the cardiac biomarkers markets. the presence of major key players in North America in the cardiac biomarkers market. All these factors are boosting the growth of the cardiac biomarkers market in North America.

Asia-Pacific is expected to grow at the fastest pace in the global cardiac biomarkers market during the forecast period. The growth can be attributed to advanced cardiac diagnostics becoming more affordable, countries modernizing, and increasing disposable income. The rising prevalence of cardiovascular diseases (CVDs) in this region has increased the demand for advanced diagnostics, government support for disease-specific research, and expenditures on healthcare. India has a greater frequency of cardiovascular diseases than other emerging countries. Hence, these factors are propelling the global cardiac biomarkers market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global cardiac biomarkers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and swot analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of overall competition within the market.

List of Key Companies  

• Roche Diagnostics Corporation
• Thermo Fisher Scientific
• Randox laboratories
• Beckman Coulter
• Siemens Healthcare
• Ortho Clinical Diagnostics
• Trinity Biotech
• Meso Scale Diagnostics
• Abbott laboratories
• BioMerieux
• Becton
• Dickinson and Co.
• Luminex Corporation
• Bio-Rad Laboratories
• Alere Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, Roche diagnostics corporation, announcement of in light of the growing burden of heart failure among T2D patients in India, inciting the need for urgent action. They are all set to release the diagnostic biomarker- NTProBNP to detect heart failure in patients and will be used in the management of Type 2 Diabetes (T2DM).

• In June 2022, Tosoh bioscience launched the ST AIA-PACK BNP assay, which is designed for use with Tosoh System Analyzers. This assay provides a non-invasive method for precisely measuring B-type natriuretic peptide (BNP) levels in blood samples, allowing patients to be evaluated for heart failure. The compact AIA-360 system is ideal for emergency rooms and can be used alongside other cardiac indicators such as troponin I, CK-MB, and myoglobin. This strategy helped the company expand its product portfolio.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global cardiac biomarkers market based on the below-mentioned segments: 

Global Cardiac Biomarkers Market, By Type

• Creatine Kinase
• Troponins
• Myoglobin
• Ischemia Modified Albumin
• Other Types

Global Cardiac Biomarkers Market, By Application

• Acute Coronary Syndrome
• Myocardial Infarction

Global Cardiac Biomarkers Market, By Biomarker

• Troponin
• Creatine kinase-MB (CK-MB)
• B-type Natriuretic Peptide (BNP)
• Myoglobin
• Others

Global Cardiac Biomarkers Market, By End User

• Hospitals
• Specialty Clinics

Global Cardiac Biomarkers Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa